Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

437 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure.
Beta-Blocker Evaluation of Survival Trial Investigators; Eichhorn EJ, Domanski MJ, Krause-Steinrauf H, Bristow MR, Lavori PW. Beta-Blocker Evaluation of Survival Trial Investigators, et al. Among authors: bristow mr. N Engl J Med. 2001 May 31;344(22):1659-67. doi: 10.1056/NEJM200105313442202. N Engl J Med. 2001. PMID: 11386264 Free article. Clinical Trial.
Nuggets, pearls, and vignettes of master heart failure clinicians. Part 4--treatment.
Leier CV, Silver MA, Rich MW, Eichhorn EJ, Fowler MB, Giles TD, Johnstone DE, Le Jemtel TH, Lachmann JS, Levine TB, Armstrong PW, Dec WG, Jessup M, Howlett J, Hershberger RE, Cohn JN, Adams KF Jr, Colucci WS, Warner-Stevenson L, Hosenpud JD, Bristow MR, Pina I, Baughman KL, Binkley PF, Ventura HO, Francis GS, White M, Miller LW, Berry B, Missov E. Leier CV, et al. Among authors: bristow mr. Congest Heart Fail. 2002 Mar-Apr;8(2):98-124. doi: 10.1111/j.1527-5299.2002.01169.x. Congest Heart Fail. 2002. PMID: 11927786 Free article. No abstract available.
Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial.
Bristow MR, Krause-Steinrauf H, Nuzzo R, Liang CS, Lindenfeld J, Lowes BD, Hattler B, Abraham WT, Olson L, Krueger S, Thaneemit-Chen S, Hare JM, Loeb HS, Domanski MJ, Eichhorn EJ, Zelis R, Lavori P. Bristow MR, et al. Circulation. 2004 Sep 14;110(11):1437-42. doi: 10.1161/01.CIR.0000141297.50027.A4. Epub 2004 Aug 30. Circulation. 2004. PMID: 15337700 Clinical Trial.
Rationale and design of the enoximone clinical trials program.
Lowes BD, Shakar SF, Metra M, Feldman AM, Eichhorn E, Freytag JW, Gerber MJ, Liard JF, Hartman C, Gorczynski R, Evans G, Linseman JV, Stewart J, Robertson AD, Roecker EB, Demets DL, Bristow MR. Lowes BD, et al. Among authors: bristow mr. J Card Fail. 2005 Dec;11(9):659-69. doi: 10.1016/j.cardfail.2005.10.013. J Card Fail. 2005. PMID: 16360960
Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial.
Feldman AM, Oren RM, Abraham WT, Boehmer JP, Carson PE, Eichhorn E, Gilbert EM, Kao A, Leier CV, Lowes BD, Mathier MA, McGrew FA, Metra M, Zisman LS, Shakar SF, Krueger SK, Robertson AD, White BG, Gerber MJ, Wold GE, Bristow MR; EMOTE Study Group. Feldman AM, et al. Among authors: bristow mr. Am Heart J. 2007 Nov;154(5):861-9. doi: 10.1016/j.ahj.2007.06.044. Epub 2007 Sep 6. Am Heart J. 2007. PMID: 17967591 Clinical Trial.
437 results